MARLBOROUGH, Mass., (Apr 5, 2006) - Cytyc Corporation, a leading women's health company, today announced that another of England's National Health Service (NHS) Strategic Health Authorities (SHA) will convert all cervical screening to the ThinPrep(R) Pap Test. The region, known as Leicestershire, Northamptonshire & Rutland (LNR), is comprised of three laboratories that process approximately 125,000 Pap tests annually. The arrangement represents a potential of approximately 625,000 ThinPrep(R) Pap Tests over the next five years.

Julie Wood, chief executive of South Leicestershire Primary Care Trust (PCT), Lead PCT for Cervical Cancer Screening on behalf of the nine Primary Care Trusts across LNR said, "All nine PCTs have invested significantly in this new technology and are pleased to support treatment that better services the women of LNR in the prevention of cervical cancer."

Alan Sharp, spokesman for the local professional implementation group that advises the PCTs said, "The decision by the SHA and its nine Primary Care Trusts was based upon rigorous examination of the evidence and all three laboratories unanimously favored Cytyc's ThinPrep Pap Test. The combination of improved clinical assurance and automation were instrumental in this decision."

"We are pleased that another region of the UK NHS has selected the ThinPrep Pap Test for all cervical screening," said David P. Harding, president, Cytyc International. "We believe our continued success is the result of our superior product and outstanding support and service provided to the NHS by the team at Cytyc UK."

About Hologic

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic's core business units are focused on mammography and breast biopsy, osteoporosis assessment, and mini C-arm and extremity MRI imaging for orthopedic applications. Cytyc's products cover a range of cancer and women's health applications, including cervical cancer screening, preterm birth screening, treatment of excessive menstrual bleeding, radiation treatment of patients with early-stage breast cancer.

MARLBOROUGH, Mass., (Apr 5, 2006) - Cytyc Corporation, a leading women's health company, today announced that another of England's National Health Service (NHS) Strategic Health Authorities (SHA) will convert all cervical screening to the ThinPrep(R) Pap Test. The region, known as Leicestershire, Northamptonshire & Rutland (LNR), is comprised of three laboratories that process approximately 125,000 Pap tests annually. The arrangement represents a potential of approximately 625,000 ThinPrep(R) Pap Tests over the next five years.

Julie Wood, chief executive of South Leicestershire Primary Care Trust (PCT), Lead PCT for Cervical Cancer Screening on behalf of the nine Primary Care Trusts across LNR said, "All nine PCTs have invested significantly in this new technology and are pleased to support treatment that better services the women of LNR in the prevention of cervical cancer."

Alan Sharp, spokesman for the local professional implementation group that advises the PCTs said, "The decision by the SHA and its nine Primary Care Trusts was based upon rigorous examination of the evidence and all three laboratories unanimously favored Cytyc's ThinPrep Pap Test. The combination of improved clinical assurance and automation were instrumental in this decision."

"We are pleased that another region of the UK NHS has selected the ThinPrep Pap Test for all cervical screening," said David P. Harding, president, Cytyc International. "We believe our continued success is the result of our superior product and outstanding support and service provided to the NHS by the team at Cytyc UK."

About Hologic

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic's core business units are focused on mammography and breast biopsy, osteoporosis assessment, and mini C-arm and extremity MRI imaging for orthopedic applications. Cytyc's products cover a range of cancer and women's health applications, including cervical cancer screening, preterm birth screening, treatment of excessive menstrual bleeding, radiation treatment of patients with early-stage breast cancer.

Forward-Looking Statements

Forward-looking statements in this press release are made pursuant to the provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements relating to Cytyc's future financial condition, operating results and economic performance, and management's expectations regarding key customer relationships, future growth opportunities, product acceptance and business strategy, constitute forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from those statements. Risks and uncertainties include, among others, dependence on key personnel and customers as well as reliance on proprietary technology, uncertainty of product development efforts and product acceptance, management of growth and product diversification, entry into new market segments domestically and new markets internationally, risks associated with litigation, the effective integration of acquired businesses and technologies, competition and competitive pricing pressures, risks associated with the FDA regulatory approval processes and healthcare reimbursement policies in the United States and abroad, introduction of technologies that are disruptive to Cytyc's business and operations, the impact of new accounting requirements and governmental rules and regulations, as well as other risks detailed in Cytyc's filings with the Securities and Exchange Commission, including under the heading "Risk Factors" in its 2005 Annual Report on Form 10-K filed with the Commission. Cytyc cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Cytyc disclaims any obligation to publicly update or revise any such statements to reflect any change in its expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Forward-looking statements in this press release are made pursuant to the provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements relating to Cytyc's future financial condition, operating results and economic performance, and management's expectations regarding key customer relationships, future growth opportunities, product acceptance and business strategy, constitute forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from those statements. Risks and uncertainties include, among others, dependence on key personnel and customers as well as reliance on proprietary technology, uncertainty of product development efforts and product acceptance, management of growth and product diversification, entry into new market segments domestically and new markets internationally, risks associated with litigation, the effective integration of acquired businesses and technologies, competition and competitive pricing pressures, risks associated with the FDA regulatory approval processes and healthcare reimbursement policies in the United States and abroad, introduction of technologies that are disruptive to Cytyc's business and operations, the impact of new accounting requirements and governmental rules and regulations, as well as other risks detailed in Cytyc's filings with the Securities and Exchange Commission, including under the heading "Risk Factors" in its 2005 Annual Report on Form 10-K filed with the Commission. Cytyc cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Cytyc disclaims any obligation to publicly update or revise any such statements to reflect any change in its expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Contact:
Glenn Muir		Frances Doria
Executive Vice President and CFO		Director, Investor Relations
Hologic, Inc.		Hologic, Inc.
Tel: 781.999.7300		Tel: 781.999.7377